Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck

被引：0
|
作者：
Jacques Bernier
机构：
[1] Genolier,J Bernier is Chairman of the Radio
[2] Switzerland.,Oncology Division at the Genolier Swiss Medical Network
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck have a poor prognosis. Cetuximab represents a clinically relevant advance in the treatment of recurrent and metastatic disease. This rationale for cetuximab as monotherapy and its use in combination with platinum-based chemotherapy for recurrent and/or metastatic disease in the first-line setting is discussed.
引用
收藏
页码：705 / 713
页数：8
相关论文
共 50 条
  • [1] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
    Bernier, Jacques
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12): : 705 - 713
  • [2] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [3] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [4] Cetuximab in the treatment of squamous cell carcinoma of the head and neck
    Specenier, Pol
    Vermorken, Jan B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (04) : 511 - 524
  • [5] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [6] Simlukafusp a and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
    Hansen, A. R.
    Gomez-Roca, C. A.
    Lolkema, M. P.
    Verlingue, L.
    Italiano, A.
    Spicer, J.
    Steeghs, N.
    Bauman, J. E.
    Fayette, J.
    Niu, J.
    Prenen, H.
    Dejardin, D.
    Boetsch, C.
    Kraxner, A.
    Evers, S.
    Vardar, T.
    Keshelava, N.
    Teichgraber, V.
    Bonomi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S805 - S805
  • [7] Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haddad, Robert, I
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 982 - 984
  • [8] Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal
    Bagust, Adrian
    Greenhalgh, Janette
    Boland, Angela
    Fleeman, Nigel
    McLeod, Claire
    Dickson, Rumona
    Dundar, Yenal
    Proudlove, Christine
    Shaw, Richard
    PHARMACOECONOMICS, 2010, 28 (06) : 439 - 448
  • [9] Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
    Yang, Chuan-Chien
    Lien, Ching-Feng
    Hwang, Tzer-Zen
    Wang, Chih-Chun
    Wang, Chien-Chung
    Shih, Yu-Chen
    Yeh, Shyh-An
    Hsieh, Meng-Che
    CANCERS, 2022, 14 (10)
  • [10] Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
    Tien-Hua Chen
    Yi-Ying Pan
    Tsung-Lun Lee
    Ling-Wei Wang
    Shyh-Kuan Tai
    Pen-Yuan Chu
    Wen-Liang Lo
    Cheng-Hsien Wu
    Muh-Hwa Yang
    Peter Mu-Hsin Chang
    BMC Cancer, 22
12345